6817.TWO Winston Medical Supply Co., Ltd.
- Market cap
- TWD 717M
- P/E
- 8.7x
- P/B
- 1.98x
- ROE
- 27.4%
- Dividend yield
- 17.97%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6817.TWO undervalued?
Graham number6817.TWO trades 12.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Winston Medical Supply Co., Ltd. fundamental analysis
No fundamental analysis for Winston Medical Supply Co., Ltd. yet.
Winston Medical Supply Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Winston Medical Supply Co., Ltd.
Winston Medical Supply Co., Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products in Taiwan and internationally. The company offers sterile ophthalmic preparations comprising gels, suspensions, solutions, and emulsions; hormone preparations, which primarily cover birth control and oral suspension for cancer related cachexia; external use preparations comprising ointments; and other oral preparations that are in oral d…
Full company profileWinston Medical Supply Co., Ltd. financial statements
Winston Medical Supply Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 365M | 505M | 537M | 607M | 709M | 695M | 700M |
| Gross Profit | 103M | 204M | 237M | 264M | 348M | 316M | 304M |
| Operating Income | -8.25M | 83.7M | 115M | 136M | 196M | 159M | 142M |
| EBITDA | 30.6M | 125M | 155M | 179M | 228M | 195M | 174M |
| Net Income | -9.36M | 99.7M | 92.1M | 111M | 159M | 132M | 117M |
| EPS | -0.27 | 2.84 | 4.99 | 6.01 | 8.58 | 7.12 | 6.37 |
| Balance Sheet | |||||||
| Total Assets | 614M | 659M | 636M | 701M | 802M | 813M | 781M |
| Total Liabilities | 441M | 375M | 311M | 340M | 374M | 373M | 353M |
| Shareholders' Equity | 173M | 284M | 325M | 362M | 428M | 439M | 428M |
| Cash & Short-term Investments | 132M | 146M | 163M | 203M | 299M | 300M | 299M |
| Total Debt | 242M | 177M | 105M | 94.4M | 107M | 103M | - |
| Cash Flow | |||||||
| Operating Cash Flow | 49.8M | 112M | 146M | 125M | 215M | 148M | 155M |
| Capital Expenditure | 6.46M | 3.20M | 5.14M | 6.55M | 20.0M | 19.3M | 17.3M |
| Free Cash Flow | 43.3M | 109M | 141M | 118M | 195M | 129M | 138M |
| Ratios | |||||||
| ROE | -5.4% | 35.2% | 28.3% | 30.8% | 37.1% | 29.9% | 27.4% |
| ROA | -1.5% | 15.1% | 14.5% | 15.9% | 19.8% | 16.2% | 15.0% |
| Net Profit Margin | -2.6% | 19.7% | 17.2% | 18.3% | 22.4% | 18.9% | 16.8% |
| Debt to Equity | 1.40x | 0.63x | 0.32x | 0.26x | 0.25x | 0.23x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Winston Medical Supply Co., Ltd. dividends
- Dividend yield
- 17.97%
- Forward dividend
- 5.00 TWD
- Payout ratio
- 109.9%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 129M | 7.00 | 109.9% |
| 2024 | TWD 122M | 6.57 | 92.4% |
| 2023 | TWD 92.1M | 4.98 | 58.0% |
| 2022 | TWD 73.7M | 3.98 | 66.2% |
| 2021 | TWD 55.3M | 2.99 | 60.0% |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Winston Medical Supply Co., Ltd.
Ownership data of Winston Medical Supply Co., Ltd. is not available yet.
Winston Medical Supply Co., Ltd. company profile
- Company name
- Winston Medical Supply Co., Ltd.
- Ticker
- 6817.TWO
- ISIN
- TW0006817000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- December
- Address
- No. 117, Ren'ai St., Tainan City, Taiwan, 710
- Phone
- 886 6253 3124
- Website
- winston.com.tw
About Winston Medical Supply Co., Ltd.
Winston Medical Supply Co., Ltd. develops, manufactures, and distributes pharmaceuticals, nutrition supplements, and cosmeceutical products in Taiwan and internationally. The company offers sterile ophthalmic preparations comprising gels, suspensions, solutions, and emulsions; hormone preparations, which primarily cover birth control and oral suspension for cancer related cachexia; external use preparations comprising ointments; and other oral preparations that are in oral dosage forms, such as powders, troches, tablets, film coated tablets, chewables, and capsules for the treatment of colds, gastrointestinal issues, and other indications. It also offers medical equipment, medical beauty products, and health food. In addition, the company engages in import and export trade; and manufacturers' agency and bidding business activities. The company was founded in 1974 and is based in Tainan City, Taiwan. Winston Medical Supply Co., Ltd. is a subsidiary of Medigen Biotechnology Corp.
Winston Medical Supply Co., Ltd. management
2- Mr. You-Zheng WangGM & Director
- Ms. Xinwen ZhangAccounting Supervisor & Assistant of Finance Department